BCG Vaccine Market to Reach USD 127.9 Million by 2031 Amid Expanding TB Prevention and Oncology Applications

The global BCG vaccine market continues to demonstrate resilient, steady growth as tuberculosis remains a persistent global health challenge and the vaccine's therapeutic applications extend beyond infectious disease prevention. New market research values the industry at USD 86.4 million in 2023, with projections showing growth to USD 90.3 million in 2024 and USD 127.9 million by 2031, a CAGR of 5.11% over the forecast period. The expansion is underpinned by intensifying global immunization strategies and rising interest in the vaccine's applications in bladder cancer treatment.

A Century-Old Vaccine With Modern Relevance

The Bacillus Calmette-Guérin (BCG) vaccine, a live attenuated vaccine derived from Mycobacterium bovis, was introduced in the early 20th century to prevent tuberculosis, particularly severe forms such as TB meningitis in children. As the only licensed vaccine for TB, it remains predominantly used in regions with high disease prevalence. While it effectively prevents severe TB in children, its efficacy against pulmonary TB in adults varies, prompting continued research into next-generation alternatives.

Tuberculosis Burden Continues to Drive Demand

The World Health Organization reported that approximately 10.6 million people globally contracted tuberculosis in 2022, comprising 5.8 million men, 3.5 million women, and 1.3 million children. Roughly 130 million children receive the BCG vaccine each year to guard against Mycobacterium tuberculosis, according to research published in bioRxiv in 2023. Tuberculosis remains especially prevalent in regions affected by poverty, homelessness, and high HIV infection rates, factors that continue to sustain demand for vaccination programs, particularly in high-risk populations including children and immunocompromised individuals.

In January 2023, the WHO established the TB Vaccine Accelerator Council to authorize and support the utilization of effective novel TB vaccines, facilitating collaboration among global agencies, funders, and governments to address development challenges. Government-backed immunization expansion, coupled with enhanced healthcare infrastructure investment, is directly fueling market growth.

Formulation Challenges and Next-Generation Development

Despite strong demand, the market faces meaningful challenges, including variable efficacy against pulmonary tuberculosis in adults and limited advances in vaccine formulation, compounded by logistical and distribution difficulties in low-resource settings where TB prevalence is highest. In response, key players are investing heavily in research to develop next-generation vaccines with improved protection profiles. In March 2024, the Bill & Melinda Gates Medical Research Institute launched a Phase 3 trial in South Africa to evaluate the M72/AS01E vaccine's effectiveness in preventing progression from latent to active TB, building on a 2019 Phase 2b trial that demonstrated roughly 50% protection against disease progression.

Strategic partnerships are also accelerating innovation. In May 2023, Spanish biopharmaceutical firm Biofabri and IAVI announced a collaboration for the comprehensive development of the tuberculosis vaccine candidate MTBVAC, part of a broader industry push toward more effective and less reactive formulations.

Beyond Tuberculosis: Expanding Therapeutic Applications

A significant trend reshaping the market is the growing use of BCG in non-tuberculosis applications, particularly bladder cancer immunotherapy and, increasingly, diabetes research. Clinical evidence demonstrating BCG's ability to reduce both recurrence and progression of bladder cancer has driven substantial adoption among healthcare providers, positioning this application as a critical growth segment. The BCG vaccine for bladder cancer segment led the overall market in 2023, reaching a valuation of USD 64.1 million, reflecting the scale of this therapeutic shift.

Segment-Level Insights

By strain, the Danish 1331 strain captured the largest market share at 36.18% in 2023, prized for its consistency, reliability, and established safety profile, and is projected to reach USD 46.6 million by 2031. By route of administration, the percutaneous method dominates the market and is expected to reach USD 79.3 million by 2031, favored for its simplicity, minimal invasiveness, and ease of integration into large-scale vaccination programs. By end user, hospitals are projected to capture the largest share at 47.64% by 2031, as they remain the primary setting for administering BCG vaccines to infants and high-risk patients, increasingly supported by advanced vaccine delivery systems and updated treatment protocols.

Regional Landscape

Asia Pacific dominates the global market, holding a 42.45% share in 2023 valued at USD 36.7 million, a position underpinned by the high prevalence of tuberculosis in countries such as India, Indonesia, and China, along with the presence of numerous domestic BCG vaccine manufacturers. The rising focus on improving vaccination rates among children across the region is expected to sustain this leadership, with Asia Pacific projected to grow at a CAGR of 5.35% and reach USD 55.3 million by 2031.

North America, while characterized by relatively low tuberculosis prevalence, is projected to grow at a CAGR of 4.54% over the forecast period, supported by targeted vaccination programs for high-risk groups and continued applications in bladder cancer treatment. Both the U.S. and Canada maintain robust government and healthcare-backed TB control initiatives, alongside established BCG manufacturers advancing vaccine research and development.

Competitive Landscape

The BCG vaccine market remains fragmented, with key players including AJ Vaccines A/S, Serum Institute of India Pvt. Ltd., GSBPL, Taj Pharmaceuticals Limited, Japan BCG Laboratory, Merck & Co., Inc., Microgen, Biomed Lublin S.A., BCG Vaccine Laboratory, and Statens Serum Institut. Companies are pursuing partnerships, mergers and acquisitions, and product innovation to expand market presence. In a notable May 2024 development, ImmunityBio entered a global supply agreement with the Serum Institute of India, the world's largest vaccine manufacturer by production volume, covering both standard BCG and a next-generation recombinant BCG intended for use alongside ImmunityBio's ANKTIVA therapy, pending regulatory approval.

Outlook

With the market projected to grow steadily to USD 127.9 million by 2031, the BCG vaccine industry is positioned at the intersection of infectious disease control and oncology innovation. Continued government investment in TB elimination programs, expanding bladder cancer applications, and next-generation vaccine research are expected to sustain demand, even as manufacturers work to address efficacy limitations and distribution challenges in the world's highest-burden regions.